Savara Inc Accrued Liabilities, Current
Savara Inc (SVRA) had Accrued Liabilities, Current of $10.60 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Accrued Liabilities, Current $10.60M.
- 2026-03-31: Accrued Liabilities, Current $11.04M.
- 2025-12-31: Accrued Liabilities, Current $14.64M.
- 2025-09-30: Accrued Liabilities, Current $12.62M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $10.60M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $11.04M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $14.64M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $12.62M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $8.88M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $6.34M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $10.18M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $8.18M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $7.90M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $6.96M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $7.09M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $5.74M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $3.38M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $3.35M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $4.53M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $4.27M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $2.90M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $2.53M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $4.88M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $5.21M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $3.49M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $4.48M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $5.58M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $5.89M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $4.45M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $6.50M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $5.47M 10-K · filed 2021-03-10 | |
| 2019-09-30 | $5.39M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $4.61M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $5.42M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $3.38M 10-K · filed 2020-03-12 | $3.33M 10-K · filed 2019-03-13 |
| 2018-09-30 | $3.91M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $2.80M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $1.95M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $2.97M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $4.15M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $5.49M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $2.24M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $2.48M 10-K · filed 2018-03-14 | $1.97M 10-K · filed 2017-03-06 |
| 2016-09-30 | $6.90M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $9.42M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $7.79M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $8.15M 10-K · filed 2017-03-06 | |
| 2015-09-30 | $7.76M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $7.84M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $6.10M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $5.63M 10-K · filed 2016-03-14 | |
| 2014-09-30 | $4.85M 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $3.48M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $3.94M 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $2.50M 10-K · filed 2015-03-24 | $2.50M 10-K · filed 2014-03-26 |
| 2013-09-30 | $2.16M 10-Q · filed 2013-11-04 | |
| 2013-06-30 | $1.58M 10-Q · filed 2013-08-05 | |
| 2013-03-31 | $1.86M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $1.28M 10-K · filed 2014-03-26 | |
| 2012-09-30 | $1.31M 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $1.24M 10-Q · filed 2012-08-06 | |
| 2012-03-31 | $986.09K 10-Q · filed 2012-05-07 | |
| 2011-12-31 | $1.12M 10-K · filed 2013-03-19 | |
| 2011-09-30 | $1.31M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $1.08M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | $864.86K 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |